149 related articles for article (PubMed ID: 9730076)
1. Open-label olanzapine treatment in five preadolescent children.
Krishnamoorthy J; King BH
J Child Adolesc Psychopharmacol; 1998; 8(2):107-13. PubMed ID: 9730076
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.
Budman CL; Gayer A; Lesser M; Shi Q; Bruun RD
J Clin Psychiatry; 2001 Apr; 62(4):290-4. PubMed ID: 11379844
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
Janowsky DS; Barnhill LJ; Davis JM
J Clin Psychiatry; 2003 Oct; 64(10):1258-65. PubMed ID: 14658977
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
Potenza MN; Holmes JP; Kanes SJ; McDougle CJ
J Clin Psychopharmacol; 1999 Feb; 19(1):37-44. PubMed ID: 9934941
[TBL] [Abstract][Full Text] [Related]
5. A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
Ross RG; Novins D; Farley GK; Adler LE
J Child Adolesc Psychopharmacol; 2003; 13(3):301-9. PubMed ID: 14642018
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.
McCracken JT; Suddath R; Chang S; Thakur S; Piacentini J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):501-8. PubMed ID: 18928414
[TBL] [Abstract][Full Text] [Related]
8. Open-label study of olanzapine in children with pervasive developmental disorder.
Kemner C; Willemsen-Swinkels SH; de Jonge M; Tuynman-Qua H; van Engeland H
J Clin Psychopharmacol; 2002 Oct; 22(5):455-60. PubMed ID: 12352267
[TBL] [Abstract][Full Text] [Related]
9. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
Karagianis JL; LeDrew KK; Walker DJ
Curr Med Res Opin; 2003; 19(6):473-80. PubMed ID: 14594518
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V
Am J Psychiatry; 1999 May; 156(5):702-9. PubMed ID: 10327902
[TBL] [Abstract][Full Text] [Related]
11. Effective open-label treatment of tourette's disorder with olanzapine.
Stamenkovic M; Schindler SD; Aschauer HN; De Zwaan M; Willinger U; Resinger E; Kasper S
Int Clin Psychopharmacol; 2000 Jan; 15(1):23-8. PubMed ID: 10836282
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study.
Mozes T; Greenberg Y; Spivak B; Tyano S; Weizman A; Mester R
J Child Adolesc Psychopharmacol; 2003; 13(3):311-7. PubMed ID: 14642019
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
15. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
Baker RW; Ames D; Umbricht DS; Chengappa KN; Schooler NR
Psychopharmacol Bull; 1996; 32(1):89-93. PubMed ID: 8927681
[TBL] [Abstract][Full Text] [Related]
16. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
Valicenti-McDermott MR; Demb H
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):549-60. PubMed ID: 17069544
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.
Stephens RJ; Bassel C; Sandor P
J Child Adolesc Psychopharmacol; 2004; 14(2):255-66. PubMed ID: 15319022
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine-induced mania.
Reeves RR; McBride WA; Brannon GE
J Am Osteopath Assoc; 1998 Oct; 98(10):549-50. PubMed ID: 9821737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
